Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05312008 · ClinicalTrials.gov registry record · Phase 2
Does Oxytocin Alter Tolerance to or Motivation for Alcohol
A Phase 2 study, sponsored by Indiana University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT05312008: Clinical Trial Phase 2 study, sponsored by Indiana University.
NCT05312008 is a Phase 2 study that was terminated before completion, run by Indiana University. The registered enrollment target is 6 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05312008, a Phase 2 study, was terminated before completion, sponsored by Indiana University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
This pilot study is intended to demonstrate feasibility and acquire preliminary data. If successful, this data could support a future project studying the effect of oxytocin on tolerance and alcohol seeking in humans.
Primary Outcome
Participants rated their subjective feeling of craving on a scale of 0-100. Tolerance to alcohol is assessed by subtracting subjective ratings at the beginning of the 2 hour alcohol infusion from ratings at the end; a negative value indicates tolerance. Possible scores ranged from -100 to 100; negative scores indicate the development of tolerance. Values reported here compare tolerance developed during the oxytocin session to tolerance developed during the placebo session.
Interventions
- DRUG Intranasal oxytocin
- DRUG Intranasal placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2022-01-16 |
| Est. Completion | 2023-12-21 |
| Phase | Phase 2 |
Why NCT05312008 stopped before completion
NCT05312008 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 2 interventions - of which Intranasal oxytocin is the first listed.
NCT05312008 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05312008 about?
NCT05312008 is a clinical study titled "Does Oxytocin Alter Tolerance to or Motivation for Alcohol". This pilot study is intended to demonstrate feasibility and acquire preliminary data. If successful, this data could support a future project studying the effect of oxytocin on tolerance and alcohol seeking in humans.
What is the current status of trial NCT05312008?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2022-01-16. Estimated completion is 2023-12-21.
What interventions are being tested in trial NCT05312008?
The interventions under investigation include: Intranasal oxytocin (DRUG), Intranasal placebo (DRUG).
Who is sponsoring clinical trial NCT05312008?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05312008's enrollment target sits among peer trials
6 1996th of 2000 higher than 1 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI